Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 109, Issue , 2016, Pages 224-235

  Balguri, Sai Prachetan ^a   Adelli, Goutham R ^a   Majumdar, Soumyajit ^a,b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN; GLYCEROL BEHENATE; INDOMETACIN; MIGLYOL; NANOPARTICLE; PENETRATION ENHANCING AGENT; SOLID LIPID NANOPARTICLE; CATION; CHLORIDE; DRUG CARRIER; EXCIPIENT; EYE DROPS; LIPID; NANOMATERIAL; NONSTEROID ANTIINFLAMMATORY AGENT; WATER;

ANIMAL EXPERIMENT; ARTICLE; CORNEA; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; HYDRODYNAMICS; IN VITRO STUDY; INFRARED SPECTROSCOPY; MALE; NONHUMAN; OCULAR TISSUE; PARTICLE SIZE; SCLERA; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; EYE; PERMEABILITY; RABBIT; SOLUBILITY; TEMPERATURE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CATIONS; CHITOSAN; CHLORIDES; CORNEA; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; EYE; INDOMETHACIN; LIPIDS; MALE; NANOPARTICLES; NANOSTRUCTURES; OPHTHALMIC SOLUTIONS; PARTICLE SIZE; PERMEABILITY; RABBITS; SCLERA; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TEMPERATURE; WATER;

EID: 84994030221     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2016.10.015     Document Type: Article

References (56)

1. [1] Toker, M.I., et al. The effects of topical ketorolac and indomethacin on measles conjunctivitis: randomized controlled trial. Am. J. Ophthalmol. 141:5 (2006), 902–905.
2. [2] Allegri, P., et al. Randomized, double-blind, placebo-controlled clinical trial on the efficacy of 0.5% indomethacin eye drops in uveitic macular edema. Invest. Ophthalmol. Vis. Sci. 55:3 (2014), 1463–1470.
3. [3] Weber, M., et al. Efficacy and safety of indomethacin 0.1% eye drops compared with ketorolac 0.5% eye drops in the management of ocular inflammation after cataract surgery. Acta Ophthalmol. 91:1 (2013), e15–e21.
4. [4] Botting, R.M., Inhibitors of cyclooxygenases: mechanisms, selectivity and uses. J. Physiol. Pharmacol. 57:Suppl. 5 (2006), 113–124.
5. [5] Russo, A., et al. Topical nonsteroidal anti-inflammatory drugs for macular edema. Mediators Inflamm., 2013, 2013, 476525.
6. [6] Kern, T.S., et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 56:2 (2007), 373–379.
7. [7] Chetoni, P., et al. Pharmacokinetics and anti-inflammatory activity in rabbits of a novel indomethacin ophthalmic solution. J. Ocul. Pharmacol. Ther. 16:4 (2000), 363–372.
8. [8] Kahanne, L.I., et al. Indosol – a nonsteroidal anti-inflammatory drug with therapeutic efficacy. Acta Pharm. Hung. 64:4 (1994), 125–129.
9. [9] Hippalgaonkar, K., et al. Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization, and in vitro evaluation. J. Ocul. Pharmacol. Ther. 29:2 (2013), 216–228.
10. [10] Patel, A., et al. Ocular drug delivery systems: an overview. World J. Pharmacol. 2:2 (2013), 47–64.
11. [11] Cholkar, K., et al. Novel nanomicellar formulation approaches for anterior and posterior segment ocular drug delivery. Recent Pat. Nanomed. 2:2 (2012), 82–95.
12. [12] Fangueiro, J.F., et al. Ocular drug delivery – new strategies for targeting anterior and posterior segments of the eye. Curr. Pharm. Des. 22:9 (2016), 1135–1146.
13. [13] Gaudana, R., et al. Ocular drug delivery. AAPS J. 12:3 (2010), 348–360.
14. [14] Morrison, P.W., Khutoryanskiy, V.V., Advances in ophthalmic drug delivery. Ther. Deliv. 5:12 (2014), 1297–1315.
15. [15] Sultana, Y., et al. Review of ocular drug delivery. Curr. Drug Deliv. 3:2 (2006), 207–217.
16. [16] Murugan, K., et al. Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures. Int. J. Nanomed. 10 (2015), 2191–2206.
17. [17] Liu, D., et al. Potential advantages of a novel chitosan-N-acetylcysteine surface modified nanostructured lipid carrier on the performance of ophthalmic delivery of curcumin. Sci. Rep., 6, 2016, 28796.
18. [18] Mainardes, R.M., et al. Colloidal carriers for ophthalmic drug delivery. Curr. Drug Targets 6:3 (2005), 363–371.
19. [19] Khare, A., et al. Mucoadhesive polymers for enhancing retention in ocular drug delivery. Progress in Adhesion and Adhesives, 2015, John Wiley & Sons, Inc., 451–484.
20. [20] Ranaldi, G., et al. The effect of chitosan and other polycations on tight junction permeability in the human intestinal Caco-2 cell line(1). J. Nutr. Biochem. 13:3 (2002), 157–167.
21. [21] Caramella, C., et al. Chitosan and its derivatives as drug penetration enhancers. J. Drug Deliv. Sci. Technol. 20:1 (2010), 5–13.
22. [22] Bonferoni, M.C., et al. Chitosan and its salts for mucosal and transmucosal delivery. Expert Opin. Drug Deliv. 6:9 (2009), 923–939.
23. [23] Uner, M., Yener, G., Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int. J. Nanomed. 2:3 (2007), 289–300.
24. [24] Liu, R., et al. Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: improving in vivo ocular bioavailability. J. Pharm. Sci. 101:10 (2012), 3833–3844.
25. [25] Jain-Vakkalagadda, B., et al. Identification and functional characterization of a Na+-independent large neutral amino acid transporter, LAT1, in human and rabbit cornea. Invest. Ophthalmol. Vis. Sci. 44:7 (2003), 2919–2927.
26. [26] Tak, R.V., et al. Transport of acyclovir ester prodrugs through rabbit cornea and SIRC-rabbit corneal epithelial cell line. J. Pharm. Sci. 90:10 (2001), 1505–1515.
27. [27] Majumdar, S., et al. Transcorneal permeation of L- and D-aspartate ester prodrugs of acyclovir: delineation of passive diffusion versus transporter involvement. Pharm. Res. 26:5 (2009), 1261–1269.
28. [28] Vadlapudi, A.D., et al. Novel biotinylated lipid prodrugs of acyclovir for the treatment of herpetic keratitis (HK): transporter recognition, tissue stability and antiviral activity. Pharm. Res. 30:8 (2013), 2063–2076.
29. [29] Ahuja, M., Dhake, A.S., Majumdar, D.K., Effect of formulation factors on in-vitro permeation of diclofenac from experimental and marketed aqueous eye drops through excised goat cornea. Yakugaku Zasshi 126:12 (2006), 1369–1375.
30. [30] Ahuja, M., et al. Topical ocular delivery of NSAIDs. AAPS J. 10:2 (2008), 229–241.
31. [31] Kim, S.J., et al. Topical Nonsteroidal Anti-inflammatory Drugs and Cataract Surgery: A Report by the American Academy of Ophthalmology. Ophthalmology 122:11 (2015), 2159–2168.
32. [32] Tres, F., et al. Indomethacin-Kollidon VA64 Extrudates: a mechanistic study of pH-dependent controlled release. Mol. Pharm. 13:3 (2016), 1166–1175.
33. [33] Bahl, D., Bogner, R.H., Amorphization alone does not account for the enhancement of solubility of drug co-ground with silicate: the case of indomethacin. AAPS PharmSciTech 9:1 (2008), 146–153.
34. [34] McMillan, J., Batrakova, E., Gendelman, H.E., Cell delivery of therapeutic nanoparticles. Prog. Mol. Biol. Transl. Sci. 104 (2011), 563–601.
35. [35] Almeida, H., et al. Nanoparticles in ocular drug delivery systems for topical administration: promises and challenges. Curr. Pharm. Des. 21:36 (2015), 5212–5224.
36. [36] Battaglia, L., et al. Application of lipid nanoparticles to ocular drug delivery. Expert Opin. Drug Deliv., 2016, 1–15.
37. [37] Chime, S.A., Onyishi, I.V., Lipid-based drug delivery systems (LDDS): recent advances and applications of lipids in drug delivery. African J. Pharm. Pharmacol. 7:48 (2013), 3034–3059.
38. [38] Uner, M., Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie 61:5 (2006), 375–386.
39. [39] De Campos, A.M., et al. The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur. J. Pharm. Sci. 20:1 (2003), 73–81.
40. [40] de la Fuente, M., Seijo, B., Alonso, M.J., Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy. Invest. Ophthalmol. Vis. Sci. 49:5 (2008), 2016–2024.
41. [41] Vllasaliu, D., et al. Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution. Int. J. Pharm. 400:1–2 (2010), 183–193.
42. [42] de Campos, A.M., et al. Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm. Res. 21:5 (2004), 803–810.
43. [43] Gukasyan, J.H., Kim, K.-J., Lee, H.L.V., The conjunctival barrier in ocular drug delivery. Ehrhardt, C., Kim, K.-J., (eds.) Drug Absorption Studies: In Situ, In Vitro And In Silico Models, 2008, Springer, US, Boston, MA, 307–320.
44. [44] He, J., et al. Preparation, pharmacokinetics and body distribution of silymarin-loaded solid lipid nanoparticles after oral administration. J. Biomed. Nanotechnol. 3:2 (2007), 195–202.
45. [45] Manjunath, K., Venkateswarlu, V., Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Drug Target 14:9 (2006), 632–645.
46. [46] Mei, D., et al. Effect of chitosan structure properties and molecular weight on the intranasal absorption of tetramethylpyrazine phosphate in rats. Eur. J. Pharm. Biopharm. 70:3 (2008), 874–881.
47. [47] Verheul, R.J., et al. Influence of the degree of acetylation on the enzymatic degradation and in vitro biological properties of trimethylated chitosans. Biomaterials 30:18 (2009), 3129–3135.
48. [48] Dale, O., et al. Transepithelial transport of morphine and mannitol in Caco-2 cells: the influence of chitosans of different molecular weights and degrees of acetylation. J. Pharm. Pharmacol. 58:7 (2006), 909–915.
49. [49] Al-Halafi, A.M., Nanocarriers of nanotechnology in retinal diseases. Saudi J. Ophthalmol. 28:4 (2014), 304–309.
50. [50] Barar, J., et al. Ocular drug delivery; impact of in vitro cell culture models. J. Ophthalmic Vis. Res. 4:4 (2009), 238–252.
51. [51] Thassu, D., Chader, G.J., Ocular Drug Delivery Systems: Barriers and Application of Nanoparticulate Systems. 2012, CRC Press.
52. [52] Liu, C.H., et al. Novel lutein loaded lipid nanoparticles on porcine corneal distribution. J. Ophthalmol., 2014, 2014, 304694.
53. [53] Castelli, F., et al. Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry. Int. J. Pharm. 304:1–2 (2005), 231–238.
54. [54] Bucolo, C., et al. Ocular pharmacokinetics profile of different indomethacin topical formulations. J. Ocul. Pharmacol. Ther. 27:6 (2011), 571–576.
55. [55] Klang, S., Abdulrazik, M., Benita, S., Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution. Pharm. Dev. Technol. 5:4 (2000), 521–532.
56. [56] Yamaguchi, M., et al. Mucoadhesive properties of chitosan-coated ophthalmic lipid emulsion containing indomethacin in tear fluid. Biol. Pharm. Bull. 32:7 (2009), 1266–1271.